Geneva Capital Management LLC Trims Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Geneva Capital Management LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,262 shares of the medical research company’s stock after selling 1,165 shares during the period. Geneva Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth $34,000. Operose Advisors LLC increased its stake in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares in the last quarter. SRS Capital Advisors Inc. lifted its holdings in Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $52,000. Finally, ORG Partners LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $66,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.3 %

Shares of EW traded up $0.26 during trading hours on Friday, reaching $87.68. The stock had a trading volume of 385,747 shares, compared to its average volume of 3,672,408. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a 50-day simple moving average of $90.03 and a 200 day simple moving average of $79.73. The company has a market capitalization of $52.84 billion, a price-to-earnings ratio of 37.68, a P/E/G ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Stifel Nicolaus upped their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Mizuho boosted their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Evercore ISI dropped their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday, April 26th. Finally, Royal Bank of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $93.27.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares in the company, valued at $14,639,824.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Bernard J. Zovighian bought 580 shares of Edwards Lifesciences stock in a transaction dated Monday, May 6th. The shares were acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 231,550 shares of company stock valued at $20,384,302. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.